Recherche
-
Benefit-risk of rivaroxaban 20 or 15mg compared to vitamin-K antagonists in patients with non-valvular atrial fibrillation: a cohort study in the French nationwide claims database
(European Heart Journal. vol. 39, pp. 1014-1014, 2018-08)Article de revue -
Reduced dose of rivaroxaban and dabigatran vs. vitamin K antagonists in very elderly patients with atrial fibrillation in a nationwide cohort study
(EP-Europace. vol. 22, n° 2, pp. 205-215, 2020)Article de revue -
Effectiveness of Cetuximab as First-Line Therapy for Patients With Wild-Type KRAS and Unresectable Metastatic Colorectal Cancer in Real-Life Practice: Results of the EREBUS Cohort
(Clinical Colorectal Cancer. vol. 17, n° 2, pp. 129-139, 2018-06)Article de revue -
Effectiveness and Safety of Rivaroxaban 15 or 20 mg Versus Vitamin K Antagonists in Nonvalvular Atrial Fibrillation
(Stroke. vol. 50, n° 9, pp. 2469-2476, 2019)Article de revueLibre accès -
Pharmacological treatment patterns in heart failure: a population-based cohort study
(Eur J Clin Pharmacol. vol. 76, n° 1, pp. 97-106, 2020)Article de revue -
Previous Drug Exposure in Patients Hospitalised for Acute Liver Injury: A Case-Population Study in the French National Healthcare Data System
(Drug safety. vol. 42, n° 4, pp. 559-572, 2019-04)Article de revue -
Effectiveness and Safety of Standard and Reduced Doses of Dabigatran Compared to Rivaroxaban in Nonvalvular Atrial Fibrillation: Long-Term Results from a Cohort Study in the French Nationwide Claims Database
(Journal of the American College of Cardiology. vol. 75, n° 11, pp. 357, 2020)Article de revue -
Six-year survival study after myocardial infarction: The EOLE prospective cohort study. Long-term survival after MI
(Thérapie. vol. 74, n° 4, pp. 459-468, 2019-09)Article de revue -
Effectiveness and safety of standard and reduced doses of dabigatran versus rivaroxaban in non-valvular atrial fibrillation: A cohort study in the snds french nationwide claims database
(Value Health. vol. 21, pp. S7-S7, 2018-10)Article de revue -
Benefit-risk profile of dabigatran compared with vitamin-K antagonists in elderly patients with non-valvular atrial fibrillation: results from a cohort study in the French nationwide claims database
(European Heart Journal. vol. 39, pp. 822-822, 2018-08)Article de revue